A Phase 3, Randomized, Open-Label, Active-Controlled Study of ALXN1210 Versus Eculizumab in Complement Inhibitor-Naive Adult Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Administered By

Duke Cancer Institute

Awarded By

Alexion Pharmaceuticals, Inc.

Contributors

de Castro III, Carlos Manuel Principal Investigator

Start/End

March 24, 2017 - October 17, 2017